TY - JOUR
T1 - A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation
AU - Psychosis Endophenotypes International Consortium
AU - The Wellcome Trust Case-Control Consortium 2
AU - Psychiatric Genomics Consortium
AU - Bramon, Elvira
AU - Pirinen, Matti
AU - Strange, Amy
AU - Lin, Kuang
AU - Freeman, Colin
AU - Bellenguez, Céline
AU - Su, Zhan
AU - Band, Gavin
AU - Pearson, Richard
AU - Vukcevic, Damjan
AU - Langford, Cordelia
AU - Deloukas, Panos
AU - Hunt, Sarah
AU - Gray, Emma
AU - Dronov, Serge
AU - Potter, Simon C.
AU - Tashakkori-Ghanbaria, Avazeh
AU - Edkins, Sarah
AU - Bumpstead, Suzannah J.
AU - Arranz, Maria J.
AU - Bakker, Steven
AU - Bender, Stephan
AU - Bruggeman, Richard
AU - Cahn, Wiepke
AU - Chandler, David
AU - Collier, David A.
AU - Crespo-Facorro, Benedicto
AU - Dazzan, Paola
AU - de Haan, Lieuwe
AU - Di Forti, Marta
AU - Dragović, Milan
AU - Giegling, Ina
AU - Hall, Jeremy
AU - Iyegbe, Conrad
AU - Jablensky, Assen
AU - Kahn, René S.
AU - Kalaydjieva, Luba
AU - Kravariti, Eugenia
AU - Lawrie, Stephen
AU - Linszen, Don H.
AU - Mata, Ignacio
AU - McDonald, Colm
AU - McIntosh, Andrew
AU - Myin-Germeys, Inez
AU - Ophoff, Roel A.
AU - Pariante, Carmine M.
AU - Paunio, Tiina
AU - Picchioni, Marco
AU - Ripke, Stephan
AU - Rujescu, Dan
N1 - Funding Information:
The Perth cohort was supported by grant 513874 of the National Health and Medical Research Council, Australia and by the North Metropolitan Health Service, Perth, Australia.
Funding Information:
M. Picchioni acknowledges a Wellcome Trust Research Training Fellowship (064971). T. Toulopoulou acknowledges the European Community’s Sixth Framework Programme through a Marie Curie Training Network (MRTN-CT-2006-035987; Local Co-PIs Murray and Toulopoulou) called the European Twin Study Network on Schizophrenia (EUTwinsS), NARSAD (through a Young Investigator Award), the Economic and Social Research Council/Medical Research Council, the Psychiatry Research Trust (PTA-037-27-0002) and the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry Kings College London. All co-authors based at the Institute of Psychiatry—King’s College London acknowledge the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry Kings College London.
Funding Information:
The Santander cohort was supported by Instituto de Salud Carlos III (PI020499, PI050427, PI060507), SENY Fundació (CI 2005-0308007), Fundacion Ramón Areces and Fundacion Marqués de Valdecilla (API07/011, API10/13).
Funding Information:
P. Donnelly was supported in part by a Royal Society Wolfson Merit Award. C. Spencer was supported by a Wellcome Trust Fellowship (097364/Z/11/Z). M. Pirinen is supported by the Academy of Finland (257654). We acknowledge use of the British 1958 Birth Cohort DNA collection funded by the Medical Research Council (grant G0000934) and the Wellcome Trust (grant 068545/Z/02), the UK National Blood Service controls funded by the Wellcome Trust and the People of the British Isles collection, funded by the Wellcome Trust. Work was supported in part by Wellcome Trust Centre for Human Genetics core grants 072894/Z/03/Z, 090532/Z/09/Z and 075491/Z/04/B.
Funding Information:
The Edinburgh cohort was supported by: a NARSAD independent investigator award and a Health Foundation Clinician Scientist Award (to A. McIntosh), a Wellcome Trust Clinical Research Training Fellowship (to Jessika Sussman) and a Royal Society Dorothy Hodgkin Fellowship (to Heather Whalley).
Funding Information:
The GROUP study was supported by: (i) The Geestkracht programme of the Dutch Health Research Council (ZON-MW, grant number 10-000-1002). (ii) The EU Seventh Framework Programme (consortium name: EU-GEI; No. HEALTH-F2-2009-241909) and matching funds from participating universities and mental health care organizations (Site Amsterdam: Academic Psychiatric Centre AMC, Ingeest, Arkin, Dijk en Duin, Rivierduinen, Erasmus MC, GGZ Noord Holland Noord; Site Utrecht: University Medical Centre Utrecht, Altrecht, Symfora, Meerkanten, Riagg Amersfoort, Delta; Site Groningen: University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Adhesie, Mediant, GGZ De Grote Rivieren and Parnassia psycho-medical centre; Site Maastricht: Maastricht University Medical Center, GGZ Eindhoven, GGZ Midden-Brabant, GGZ Oost-Brabant, GGZ Noord- Midden Limburg, Mondriaan Zorggroep, Prins Clauscentrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem). (iii) NIMH grant to R.A. Ophoff (1R01MH078075).
Funding Information:
The Heidelberg cohort work was supported by a grant (WE-1996/1-3) from the German Research Community (Deutsche Forschungsgemeinschaft, DFG) to M. Weisbrod. We would like to thank Dr. Anuradha Sharma for her help with the management of the Heidelberg dataset.
Funding Information:
The principal funding for this study was provided by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project (Grant Nos. 085475/B/08/Z and 085475/Z/08/Z).
Funding Information:
E. Bramon currently holds a MRC New Investigator Award and a MRC Centenary Award. E. Bramon was further supported by the National Institute of Health Research UK (post-doctoral fellowship), the Psychiatry Research Trust, the Schizophrenia Research Fund, the Brain and Behavior Research foundation’s (NARSAD’s) Young Investigator Award, a Wellcome Trust Research Training Fellowship and the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry Kings College London.
Funding Information:
B. Crespo-Facorro has received honoraria for his participation as a speaker at educational events from Bristol-Myers Squibb and Johnson & Johnson. J. Jankowski is a consultant to Astra Zeneca. S. Lawrie, A. McIntosh, J. Hall and H. Whalley have all received support from Pfizer (formerly Wyeth) for imaging studies of schizophrenia and bipolar disorder. M. Picchioni receives financial support from Pfizer and Janssen Cilag. J. Van Os has received unrestricted investigator-led research grants or recompense for presenting his research from Eli Lilly, Bristol-Myers Squibb, Lundbeck, Organon, Janssen-Cilag, GlaxoSmithKline, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. All other co-authors declare no biomedical financial interests or potential conflict of interests.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Background Genome-wide association studies (GWAS) have identified several loci associated with schizophrenia and/or bipolar disorder. We performed a GWAS of psychosis as a broad syndrome rather than within specific diagnostic categories. Methods 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder; 857 of their unaffected relatives, and 2739 healthy controls were genotyped with the Affymetrix 6.0 single nucleotide polymorphism (SNP) array. Analyses of 695,193 SNPs were conducted using UNPHASED, which combines information across families and unrelated individuals. We attempted to replicate signals found in 23 genomic regions using existing data on nonoverlapping samples from the Psychiatric GWAS Consortium and Schizophrenia-GENE-plus cohorts (10,352 schizophrenia patients and 24,474 controls). Results No individual SNP showed compelling evidence for association with psychosis in our data. However, we observed a trend for association with same risk alleles at loci previously associated with schizophrenia (one-sided p =.003). A polygenic score analysis found that the Psychiatric GWAS Consortium's panel of SNPs associated with schizophrenia significantly predicted disease status in our sample (p = 5 × 10-14) and explained approximately 2% of the phenotypic variance. Conclusions Although narrowly defined phenotypes have their advantages, we believe new loci may also be discovered through meta-analysis across broad phenotypes. The novel statistical methodology we introduced to model effect size heterogeneity between studies should help future GWAS that combine association evidence from related phenotypes. Applying these approaches, we highlight three loci that warrant further investigation. We found that SNPs conveying risk for schizophrenia are also predictive of disease status in our data.
AB - Background Genome-wide association studies (GWAS) have identified several loci associated with schizophrenia and/or bipolar disorder. We performed a GWAS of psychosis as a broad syndrome rather than within specific diagnostic categories. Methods 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder; 857 of their unaffected relatives, and 2739 healthy controls were genotyped with the Affymetrix 6.0 single nucleotide polymorphism (SNP) array. Analyses of 695,193 SNPs were conducted using UNPHASED, which combines information across families and unrelated individuals. We attempted to replicate signals found in 23 genomic regions using existing data on nonoverlapping samples from the Psychiatric GWAS Consortium and Schizophrenia-GENE-plus cohorts (10,352 schizophrenia patients and 24,474 controls). Results No individual SNP showed compelling evidence for association with psychosis in our data. However, we observed a trend for association with same risk alleles at loci previously associated with schizophrenia (one-sided p =.003). A polygenic score analysis found that the Psychiatric GWAS Consortium's panel of SNPs associated with schizophrenia significantly predicted disease status in our sample (p = 5 × 10-14) and explained approximately 2% of the phenotypic variance. Conclusions Although narrowly defined phenotypes have their advantages, we believe new loci may also be discovered through meta-analysis across broad phenotypes. The novel statistical methodology we introduced to model effect size heterogeneity between studies should help future GWAS that combine association evidence from related phenotypes. Applying these approaches, we highlight three loci that warrant further investigation. We found that SNPs conveying risk for schizophrenia are also predictive of disease status in our data.
KW - Bipolar disorder
KW - genome-wide association
KW - meta-analysis
KW - polygenic score analysis
KW - psychosis
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84893814574&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2013.03.033
DO - 10.1016/j.biopsych.2013.03.033
M3 - Article
C2 - 23871474
AN - SCOPUS:84893814574
SN - 0006-3223
VL - 75
SP - 386
EP - 397
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 5
ER -